Cathepsin k
From Proteopedia
(Undo revision 2585744 by Lauren Sharpe (Talk)) |
|||
Line 2: | Line 2: | ||
==Introduction== | ==Introduction== | ||
- | Cathepsin K is the most abundant cysteine protease produced by osteoclasts, the multinuclear cells responsible for bone resorption <ref name="stoch">doi:10.1038/sj.clpt.6100450</ref><ref name="vaan">doi:10.1016/j.addr.2004.12.018</ref>. Osteoclasts implement bone resorption in two sequential processes. First, acid is secreted onto the bone surface to demineralize the bone tissue <ref name="zao"/><ref name="stoch"/>. | + | |
+ | Cathepsin K is the most abundant cysteine protease produced by osteoclasts, the multinuclear cells responsible for bone resorption <ref name="stoch">doi:10.1038/sj.clpt.6100450</ref><ref name="vaan">doi:10.1016/j.addr.2004.12.018</ref>. Osteoclasts implement bone resorption in two sequential processes. First, acid is secreted onto the bone surface to demineralize the bone tissue <ref name="zao">doi:10.1038/nsb0297-109</ref><ref name="stoch"/>. Second, the acid secretion and consequential decrease in pH results in the activation of proteases – including cathepsin k – which degrade the bone matrix <ref name="zao"/><ref name="stoch"/>. | ||
Cathepsin K is also found in macrophages, cells involved in the reception and destruction of cholesterol <ref name="lind"/>. | Cathepsin K is also found in macrophages, cells involved in the reception and destruction of cholesterol <ref name="lind"/>. | ||
Line 10: | Line 11: | ||
<scene name='72/727885/Cathepsin_k_helix_sheet/1'>Cathepsin K</scene> is initially synthesized in its inactive form, pre-procathepsin k, a 37-kDa protein made up of a single peptide chain 329 amino acids in length <ref name="mcq">doi:10.1074/jbc.272.21.13955</ref><ref name="boss">doi:10.1074/jbc.271.21.12517</ref>. The pre-procathepsin k sequence has three distinct features: a signal peptide, consisting of the first 15 amino acids at the N-terminus; a propeptide, comprising amino acids 16-114; and the main chain, which makes up the final 215 amino acids ending at the C-Terminus <ref name="uniprot">http://www.uniprot.org/uniprot/P43235#structure</ref><ref name="protparam">"CATK_HUMAN (P43235)." http://web.expasy.org/protparam</ref>. When the enzyme is activated, the signal peptide and propeptide portions are cleaved to produce the mature Cathepsin K protein weighing 27-kDa <ref name="mcq"/><ref name="boss"/>. | <scene name='72/727885/Cathepsin_k_helix_sheet/1'>Cathepsin K</scene> is initially synthesized in its inactive form, pre-procathepsin k, a 37-kDa protein made up of a single peptide chain 329 amino acids in length <ref name="mcq">doi:10.1074/jbc.272.21.13955</ref><ref name="boss">doi:10.1074/jbc.271.21.12517</ref>. The pre-procathepsin k sequence has three distinct features: a signal peptide, consisting of the first 15 amino acids at the N-terminus; a propeptide, comprising amino acids 16-114; and the main chain, which makes up the final 215 amino acids ending at the C-Terminus <ref name="uniprot">http://www.uniprot.org/uniprot/P43235#structure</ref><ref name="protparam">"CATK_HUMAN (P43235)." http://web.expasy.org/protparam</ref>. When the enzyme is activated, the signal peptide and propeptide portions are cleaved to produce the mature Cathepsin K protein weighing 27-kDa <ref name="mcq"/><ref name="boss"/>. | ||
- | The <scene name='72/727885/Cathepsin_k_active_site/1'>active site</scene> of Cathepsin K consists of three residues: CYS25, HIS162, and ASN182 <ref name="zao" | + | The <scene name='72/727885/Cathepsin_k_active_site/1'>active site</scene> of Cathepsin K consists of three residues: CYS25, HIS162, and ASN182 <ref name="zao"/>. The cleft containing the active site is flanked by two large globular domains <ref name="zao"/><ref name="lut">doi:10.1096/fj.06-7924com</ref>. Protease activity is induced by the entrance of the substrate into the active site cleft <ref name="lut"/>. |
- | This cysteine protease is active in acidic conditions, within a pH range of 4 to 6 <ref name="lind"/><ref name="lut"/><ref name="garn"/>. | + | This cysteine protease is active in acidic conditions, within a pH range of 4 to 6 <ref name="lind"/><ref name="lut"/><ref name="garn">doi:10.1074/jbc.273.48.32347</ref>. |
== Function == | == Function == | ||
- | Cathepsin K can cleave type I and type II collagen, major components of bone and cartilage matrices <ref name="hou">doi:10.1016/S0002-9440(10)63068-4</ref> <ref name="kaf">DOI: 10.1042/bj3310727</ref>. This enzyme is unique among other cysteine proteases in that it can cleave collagen at multiple sites and in its triple helix <ref name="garn" | + | Cathepsin K can cleave type I and type II collagen, major components of bone and cartilage matrices <ref name="hou">doi:10.1016/S0002-9440(10)63068-4</ref> <ref name="kaf">DOI: 10.1042/bj3310727</ref>. This enzyme is unique among other cysteine proteases in that it can cleave collagen at multiple sites and in its triple helix <ref name="garn"/>. |
Cathepsin K is also capable of degrading apolipoproteins, which reside in macrophages and facilitate the efflux of cholesterol from these cells <ref name="lind"> doi:10.1016/j.bbrc.2003.11.020</ref>. Cathepsin K can promote the accumulation of cholesterol in macrophages and promote the production of foam cells, which are major components of atherosclerotic plaque in arteries <ref name="lind"/>. | Cathepsin K is also capable of degrading apolipoproteins, which reside in macrophages and facilitate the efflux of cholesterol from these cells <ref name="lind"> doi:10.1016/j.bbrc.2003.11.020</ref>. Cathepsin K can promote the accumulation of cholesterol in macrophages and promote the production of foam cells, which are major components of atherosclerotic plaque in arteries <ref name="lind"/>. |
Revision as of 14:23, 6 April 2016
|
Contents |
Introduction
Cathepsin K is the most abundant cysteine protease produced by osteoclasts, the multinuclear cells responsible for bone resorption [1][2]. Osteoclasts implement bone resorption in two sequential processes. First, acid is secreted onto the bone surface to demineralize the bone tissue [3][1]. Second, the acid secretion and consequential decrease in pH results in the activation of proteases – including cathepsin k – which degrade the bone matrix [3][1].
Cathepsin K is also found in macrophages, cells involved in the reception and destruction of cholesterol [4].
Structure
is initially synthesized in its inactive form, pre-procathepsin k, a 37-kDa protein made up of a single peptide chain 329 amino acids in length [5][6]. The pre-procathepsin k sequence has three distinct features: a signal peptide, consisting of the first 15 amino acids at the N-terminus; a propeptide, comprising amino acids 16-114; and the main chain, which makes up the final 215 amino acids ending at the C-Terminus [7][8]. When the enzyme is activated, the signal peptide and propeptide portions are cleaved to produce the mature Cathepsin K protein weighing 27-kDa [5][6].
The of Cathepsin K consists of three residues: CYS25, HIS162, and ASN182 [3]. The cleft containing the active site is flanked by two large globular domains [3][9]. Protease activity is induced by the entrance of the substrate into the active site cleft [9].
This cysteine protease is active in acidic conditions, within a pH range of 4 to 6 [4][9][10].
Function
Cathepsin K can cleave type I and type II collagen, major components of bone and cartilage matrices [11] [12]. This enzyme is unique among other cysteine proteases in that it can cleave collagen at multiple sites and in its triple helix [10].
Cathepsin K is also capable of degrading apolipoproteins, which reside in macrophages and facilitate the efflux of cholesterol from these cells [4]. Cathepsin K can promote the accumulation of cholesterol in macrophages and promote the production of foam cells, which are major components of atherosclerotic plaque in arteries [4].
Disease
Deficiencies in Cathepsin K have been shown to cause pycnodysostosis, caused by reduced bone resorption and characterized by increased bone density and short stature [13]. Cathepsin K inhibitors have been thus thought potential treatments for diseases involving excessive bone or cartilage resorption, such as osteoporosis and autoimmune arthritis [1][11][14]. However, as demineralization of bone can continue without Cathepsin k, the inhibition of Cathespin K may merely result in the accumulation of weakened bone tissue [2].
Cathepsin K may also take part in atherosclerosis.
Relevance
</StructureSection>
References
- ↑ 1.0 1.1 1.2 1.3 Stoch SA, Wagner JA. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin Pharmacol Ther. 2008 Jan;83(1):172-6. Epub 2007 Dec 12. PMID:18073778 doi:http://dx.doi.org/10.1038/sj.clpt.6100450
- ↑ 2.0 2.1 Vaananen K. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics. Adv Drug Deliv Rev. 2005 May 25;57(7):959-71. Epub 2005 Apr 15. PMID:15876398 doi:http://dx.doi.org/10.1016/j.addr.2004.12.018
- ↑ 3.0 3.1 3.2 3.3 doi: https://dx.doi.org/10.1038/nsb0297-109
- ↑ 4.0 4.1 4.2 4.3 doi: https://dx.doi.org/10.1016/j.bbrc.2003.11.020
- ↑ 5.0 5.1 doi: https://dx.doi.org/10.1074/jbc.272.21.13955
- ↑ 6.0 6.1 doi: https://dx.doi.org/10.1074/jbc.271.21.12517
- ↑ http://www.uniprot.org/uniprot/P43235#structure
- ↑ "CATK_HUMAN (P43235)." http://web.expasy.org/protparam
- ↑ 9.0 9.1 9.2 doi: https://dx.doi.org/10.1096/fj.06-7924com
- ↑ 10.0 10.1 doi: https://dx.doi.org/10.1074/jbc.273.48.32347
- ↑ 11.0 11.1 Hou WS, Li Z, Gordon RE, Chan K, Klein MJ, Levy R, Keysser M, Keyszer G, Bromme D. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am J Pathol. 2001 Dec;159(6):2167-77. PMID:11733367 doi:http://dx.doi.org/10.1016/S0002-9440(10)63068-4
- ↑ doi: https://dx.doi.org/10.1042/bj3310727
- ↑ doi: https://dx.doi.org/10.1126/science.273.5279.1236
- ↑ Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science. 2008 Feb 1;319(5863):624-7. doi: 10.1126/science.1150110. PMID:18239127 doi:http://dx.doi.org/10.1126/science.1150110